Fennec Pharmaceuticals stock jumps after Q1 earnings beat, driven by stronger PEDMARK sales and rising pediatric treatment demand.
Stock Earnings Results
May 14, 2026
Table of Contents
May 14, 2026
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) rose 26.96% after reporting first-quarter 2026 results above expectations, supported by higher PEDMARK sales, stronger demand, and early benefits from its expanded field sales team.
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on PEDMARK, a treatment used to reduce the risk of cisplatin-induced hearing loss in pediatric patients.
The company reported EPS of $0.01, above estimates for a loss of $0.02, representing a 150.0% earnings surprise. Revenue came in at $15.11 million, above estimates of $13.94 million, with revenue growth of 72.6%.
Fennec reported net product sales of $15.1 million in the first quarter, up from $8.8 million in the prior-year quarter.
The increase was driven by growth across PEDMARK accounts, including new accounts in the adolescent and young adult population. Management also said established prescribers showed growing confidence in PEDMARK, leading to deeper utilization and higher vials per account.
Fennec said its field sales expansion is showing early signs of positive results, with record PEDMARK demand in April 2026.
The company also said its Fennec HEARS patient services program is helping improve patient access and conversion rates, supporting broader utilization of PEDMARK.
Fennec initiated a third institution-led clinical study evaluating PEDMARK in adolescent and young adult and adult patients with head and neck and testicular cancers receiving cisplatin.
The company also said four PEDMARK abstracts were accepted for the 2026 ASCO Annual Meeting, giving investors upcoming clinical visibility around broader use cases.
Selling and marketing expenses rose to $11.4 million from $3.2 million a year earlier.
The increase was tied to PEDMARK commercialization, sales organization expansion, and expense reclassification. General and administrative expenses fell to $3.2 million from $5.9 million as legal and professional costs declined after litigation activities concluded.
Fennec ended the quarter with $40.1 million in cash and cash equivalents, up from $36.8 million at the end of 2025.
The company said current cash, cash equivalents, investment securities, and projected PEDMARK revenue should be sufficient to fund the business under its current operating plan.
Investors are likely to watch whether Fennec can sustain PEDMARK demand and convert broader clinical interest into a larger commercial opportunity.
The key areas are:
Fennec’s quarter was strong because revenue growth, EPS upside, and commercial execution all moved in the right direction.
The market reaction suggests investors viewed PEDMARK demand as gaining traction, especially with record April demand and broader clinical studies underway. The next test is whether the company can keep growing revenue while managing the higher selling costs needed to expand adoption.
Platforms like LevelFields track earnings beats, FDA approvals, leadership changes, and buybacks, helping investors identify when small-cap biotech and specialty pharma companies are moving on real commercial traction.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE